Electronic Resource

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

Bibliographic Details
Title: Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
Source: Targeted oncology, 4 (2
Publisher Information: 2009-04
Added Details: Azambuja, Evandro
Bedard, Philippe L
Suter, T.
Piccart-Gebhart, Martine
Document Type: Electronic Resource
Abstract: Trastuzumab, a monoclonal antibody that blocks HER-2 receptor, improves the survival of women with HER-2-positive early and advanced breast cancer when given with chemotherapy. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER-2, is approved for the treatment of metastatic breast cancer patients after failure of prior anthracycline, taxanes and trastuzumab therapies in combination with capecitabine. Importantly, cardiac toxicity, manifested as symptomatic congestive heart failure or asymptomatic left ventricular ejection fraction decline, has been reported in some of the patients receiving these novel anti-HER-2 therapies, particularly when these drugs are used following anthracyclines, whose cardiotoxic potential has been recognized for decades. This review will focus on the incidence, natural history, underlying mechanisms, management, and areas of uncertainty regarding trastuzumab-and lapatinib-induced cardiotoxicity.
Journal Article
Index Terms: Sciences bio-médicales et agricoles, Adjuvants, Immunologic -- administration & dosage, Anthracyclines -- administration & dosage, Antibodies, Monoclonal -- administration & dosage, Antibodies, Monoclonal -- adverse effects, Breast Neoplasms -- immunology, Breast Neoplasms -- mortality, Breast Neoplasms -- pathology, Breast Neoplasms -- physiopathology, Breast Neoplasms -- therapy, Drug Resistance, Neoplasm, Female, Heart Failure -- chemically induced, Humans, Oxidative Stress, Protein Kinase Inhibitors -- administration & dosage, Protein Kinase Inhibitors -- adverse effects, Quinazolines -- administration & dosage, Quinazolines -- adverse effects, Receptor, Epidermal Growth Factor -- antagonists & inhibitors, Receptor, erbB-2 -- antagonists & inhibitors, Receptor, erbB-2 -- immunology, Survival Rate, Ventricular Outflow Obstruction -- chemically induced, Anti-HER-2 therapies, Breast cancer, Cardiotoxicity, Lapatinib, Trastuzumab, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/52366
Availability: Open access content. Open access content
Note: No full-text files
Other Numbers: EQY oai:dipot.ulb.ac.be:2013/52366
From OAIster®, provided by the OCLC Cooperative.
Accession Number: edsoai.ocn764587181
Database: OAIster
Description not available.